Ideaya Net Income From Continuing Ops from 2010 to 2026
| IDYA Stock | USD 32.99 0.66 1.96% |
Net Loss | First Reported 2018-03-31 | Previous Quarter -77.5 M | Current Value 119.2 M | Quarterly Volatility 38.3 M |
Check Ideaya Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ideaya Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 63.4 M, Interest Income of 63.4 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 283, Dividend Yield of 0.0 or PTB Ratio of 1.87. Ideaya financial statements analysis is a perfect complement when working with Ideaya Biosciences Valuation or Volatility modules.
Ideaya | Net Income From Continuing Ops | Build AI portfolio with Ideaya Stock |
Analyzing Ideaya Biosciences's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing Ideaya Biosciences's current valuation and future prospects.
Latest Ideaya Biosciences' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Ideaya Biosciences over the last few years. It is Ideaya Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ideaya Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Ideaya Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (69,604,361) | |
| Coefficient Of Variation | (130.99) | |
| Mean Deviation | 69,497,375 | |
| Median | (34,346,000) | |
| Standard Deviation | 91,175,555 | |
| Sample Variance | 8313T | |
| Range | 262.6M | |
| R-Value | (0.80) | |
| Mean Square Error | 3206T | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | (14,426,798) | |
| Total Sum of Squares | 133007.7T |
Ideaya Net Income From Continuing Ops History
About Ideaya Biosciences Financial Statements
Ideaya Biosciences stakeholders use historical fundamental indicators, such as Ideaya Biosciences' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Ideaya Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ideaya Biosciences' assets and liabilities are reflected in the revenues and expenses on Ideaya Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ideaya Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -247 M | -234.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Check out the analysis of Ideaya Biosciences Correlation against competitors. For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ideaya Biosciences. Market participants price Ideaya higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Ideaya Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.89) | Revenue Per Share | Quarterly Revenue Growth 0.785 | Return On Assets | Return On Equity |
The market value of Ideaya Biosciences is measured differently than its book value, which is the value of Ideaya that is recorded on the company's balance sheet. Investors also form their own opinion of Ideaya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ideaya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ideaya Biosciences' market value can be influenced by many factors that don't directly affect Ideaya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ideaya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ideaya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Ideaya Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.